循環器ジャーナル65巻1号

2017年01月発行

特集 Clinical Scenarioによる急性心不全治療 Ⅲ．Clinical Scenario 1：起坐呼吸を呈する急性心不全

急性心不全治療薬としての血管拡張薬のエビデンス

著者： 佐藤幸人¹

所属機関： ¹兵庫県立尼崎総合医療センター循環器内科

ページ範囲：P.30 - P.35

Point
・硝酸薬は血行動態の改善のために経験的に臨床で用いられている古典的薬剤であるが，大規模試験のエビデンスはない．
・ナトリウム利尿ペプチドは血行動態改善作用があるが，長期予後改善効果はエビデンスがない．
・リラキシンは現在，血行動態改善と長期予後改善効果を検討中の今後の薬剤である．

参考文献

1) Cotter G, Metzkor E, Kaluski E, et al:Randomized trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose frosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351:389-393, 1998

2) Sharon A, Shpirer I, Kaluski E, et al:High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 36:832-837, 2000

3) Publication Committee for the VMAC Investigators（Vasodilatation in the Management of Acute CHF):Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial. JAMA 287:1531-1540, 2002

4) Abraham WT, Adams KF, Fonarow GC, et al:In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. An analysis from the Acute Decompensated Heart Failure National Registry（ADHERE). J Am Coll Cardiol 46:57-64, 2005

5) Sackner-Bernstein JD, Skopicki HA, Aaronson KD:Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111:1487-1491, 2005

6) Sackner-Bernstein JD, Kowalski M, Fox M, et al:Short-term risk of death after treatment with nesiritide for decompensated heart failure. JAMA 293:1900-1905, 2005

7) O' Connor CM, Starling RC, Hernandez AF, et al:Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32-43, 2011. doi:10.1056/NEJMoa1100171

8) Chen HH, Anstrom KJ, Givertz MM, et al:Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction:the ROSE acute heart failure randomized trial. JAMA 310:2533-2543, 2013. doi:10.1001/jama. 2013.282190

9) Hata N, Seino Y, Tsutamoto T, et al:Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure:the PROTECT multicenter randomized controlled study. Circ J 72:1787-1793, 2008. Epub 2008 Sep 24

10) Nomura F, Kurobe N, Mori Y, et al:Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure:COMPASS:Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ J 72:1777-1786, 2008. Epub 2008 Oct 3

11) Matsue Y, Kagiyama N, Yoshida K, et al:Carperitide is associated with increased in-hospital mortality in acute heart failure:a propensity score-matched analysis. J Card Fail 21:859-864, 2015. doi:10.1016/j.cardfail.2015.05.007. Epub 2015 May 18

12) Teerlink JR, Metra M, Felker GM, et al:Relaxin for the treatment of patients with acute heart failure（Pre-RELAX-AHF):a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373:1429-1439, 2009. doi:10.1016/S0140-6736(09)60622-X. Epub 2009 Mar 28

13) Teerlink JR, Cotter G, Davison BA, et al:Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure（RELAX-AHF):a randomised, placebo-controlled trial. Lancet 381:29-39, 2013. doi:10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7